4Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001, 29(7):1303-1310.
5Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guideline. Infect Control Hosp Epidemiol, 1996, 17(6):356-359.
6Snider RH, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med, 1997, 45(9):552-560.
7American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med, 1992, 20(6):864-874.
8Vincent JL, Moreno R, Takala J, et al. The SOFA score to describe organ dysfunction/failure. Intensive Care Med,1996, 22(7):707-710.
9Oberhoffer M, Vogelsang H, Russwurm S, et al. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med, 1999, 37(3):363-368.
10Hausfater P, Garric S, Ayed B, et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis,2002, 34(7):895-901.
8Almirall J,Bolibar I,Toran P,et al.Contribution of C-reactive protein to the diagnosis and assessment of severity of communityacquired pneumonia[J].Chest,2004,125(4):1335-1342.
9Casado Flores J,Blanco Ouiros A.Procalcitionin,A new marker for bacterial infection[J].An Esp Pediatr,2001,54(1):69-73.
10Cattas DJ,Cook DJ.Procalcitonin as a diagnostic test for sepsis:health technology assessment in the ICU[J].J Crit Care,2003,18(1):52-58.
